{
    "nct_id": "NCT04670679",
    "official_title": "An Open-Label, Multi-Center Phase 1/1b Dose Escalation and Expansion Study of ERAS-601 SHP2 Inhibitor as a Monotherapy and in Combination With Other Anti-Cancer Therapies in Patients With Advanced or Metastatic Solid Tumors",
    "inclusion_criteria": "* Age ≥ 18 years\n* Willing and able to give written informed consent\n* Have histologically or cytologically confirmed advanced or metastatic solid tumor\n* There is no available standard systemic therapy available for the patient's tumor histology and/or molecular biomarker profile; or standard therapy is intolerable, not effective, or not accessible; or patient has refused standard therapy\n* Able to swallow oral medication\n* Have Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 or 1\n* Adequate cardiovascular, hematological, liver, and renal function\n* Willing to comply with all protocol-required visits, assessments, and procedures\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 99 Years",
    "exclusion_criteria": "* Previous treatment with a SHP2 inhibitor\n* Documented PTPN11 mutations\n* Is currently receiving another study therapy or has participated in a study of an investigational agent and received study therapy within 4 weeks of the first dose of ERAS-601\n* Received prior palliative radiation within 7 days of Cycle 1, Day 1\n* Have primary central nervous system (CNS) disease or known active CNS metastases and/or carcinomatous meningitis\n* Prior surgery (e.g., gastric bypass surgery, gastrectomy) or gastrointestinal dysfunction (e.g., Crohn's disease, ulcerative colitis, short gut syndrome) that may affect drug absorption\n* Active, clinically significant interstitial lung disease or pneumonitis\n* History of thromboembolic or cerebrovascular events ≤ 12 weeks prior to the first dose of study treatment\n* History or current evidence of retinal vein occlusion (RVO) or current risk factors for RVO\n* Have any underlying medical condition, psychiatric condition, or social situation that, in the opinion of the Investigator, would compromise study administration as per protocol or compromise the assessment of AEs\n* Are pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the trial",
    "miscellaneous_criteria": ""
}